Skip to Content
Merck
All Photos(2)

Documents

R1402

Sigma-Aldrich

Raloxifene hydrochloride

solid

Synonym(s):

Keoxifene hydrochloride, LY 156758, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C28H27NO4S · HCl
CAS Number:
82640-04-8
Molecular Weight:
510.04
MDL number:
MFCD01938233
UNSPSC Code:
51111800
PubChem Substance ID:
24278673
NACRES:
NA.77

form

solid

Quality Level

100

color

light yellow

solubility

DMSO: soluble 28 mg/mL
H2O: insoluble

originator

Eli Lilly

SMILES string

Cl[H].Oc1ccc(cc1)-c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4

InChI

1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H

InChI key

BKXVVCILCIUCLG-UHFFFAOYSA-N

Gene Information

human ... ESR2(2100)

Looking for similar products? Visit Product Comparison Guide

Application

Raloxifene hydrochloride has been used:
  • as a competitive inhibitors for estrogen receptor α in breast cancer cells
  • as an anti-resorptive agents to test its effect on improving bone mineral density (BMD) in six-month-old female ovariectomized rats
  • to test effect on viability of esophageal adenocarcinoma cells

Biochem/physiol Actions

Raloxifene is benzothiophene compound and is used in treating postmenopausal osteoporosis It comparatively induces lesser risk in developing thromboembolic events and cataracts compared to tamoxifen. Raloxifene also interacts with estrogen receptors and plasma proteins.
Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H351 - H361d

Hazard Classifications

Carc. 2 - Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 10

1 of 10

Phthalazine 98%

Sigma-Aldrich

P38706

Phthalazine

Exemestane ≥98% (HPLC)

Sigma-Aldrich

PZ0006

Exemestane

β-Lapachone ≥98% (TLC)

Sigma-Aldrich

L2037

β-Lapachone

Letrozole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1540

Letrozole

Rifabutin >98% (HPLC), powder

Sigma-Aldrich

R3530

Rifabutin

Tofacitinib citrate ≥98% (HPLC)

Sigma-Aldrich

PZ0017

Tofacitinib citrate

Anastrozole ≥98% (HPLC)

Sigma-Aldrich

A2736

Anastrozole

Letrozole ≥98% (HPLC)

Sigma-Aldrich

L6545

Letrozole

Flutamide

Sigma-Aldrich

F9397

Flutamide

N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride BioXtra

Sigma-Aldrich

E1769

N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride

Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects
Muchmore DB
Oncologist, 5(5), 388-392 (2000)
Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
Stern AR, et al.
BoneKEy reports, 8, 115-124 (2018)
Raloxifene
Moen MD, et al.
Drugs (2008)
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
Fanning SW, et al.
eLife, 7, e37161-e37161 (2018)
Effects of chemotherapy agents on Sphingosine-1-Phosphate receptors expression in MCF-7 mammary cancer cells
Ghosal P, et al.
Biomedicine and Pharmacotherapy, 81, 218-224 (2016)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service